目的 探讨胆宁片联合托尼萘酸片治疗非酒精性脂肪肝的临床疗效。方法 选取2016年7月—2018年1月新乡市中心医院收治的102例非酒精性脂肪肝患者为研究对象，根据随机区组设计法将患者分为对照组（51例）和治疗组（51例）。对照组患者于饭前30 min口服托尼萘酸片，2片/次，3次/d。治疗组在对照组治疗的基础上口服胆宁片，5片/次，3次/d。两组均连续治疗3个月。观察两组患者的临床疗效，同时比较两组治疗前后的体质量指数（BMI）、肝功能、血脂、肝脏CT检查结果和血清指标。结果 治疗后，治疗组患者的总有效率为98.0%，显著高于对照组的82.4%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组BMI、丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、三酰甘油（TG）和总胆固醇（TC）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组BMI、ALT、AST、TG和TC水平均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的脂肪肝轻重程度分布、肝/脾CT值均显著改善，两组比较差异具有统计学意义（P<0.05）；治疗后，治疗组脂肪肝轻重程度分布、肝/脾CT值显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组超氧化物歧化酶（SOD）显著升高，丙二醛（MDA）、肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组SOD显著高于对照组，MDA、TNF-α均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 胆宁片联合托尼萘酸片治疗非酒精性脂肪肝的疗效显著，可有效降低患者脂肪肝程度，改善肝功能，具有一定临床应用价值。

Objective To investigate the clinical effect of Danning Tablets combined with Tolynicate and Naphthylacetic Acid Tablets in treatment of non-alcoholic fatty liver. Methods Patients (102 cases) with non- alcoholic fatty liver in Xinxiang Central Hospital from July 2016 to January 2018 were randomly divided into control (51 cases) and treatment (51 cases) groups. Patients in the control group were po administered with Tolynicate and Naphthylacetic Acid Tablets 30 min before meals, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Danning Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the BMI, liver function, blood lipid, liver CT findings, and serum indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 98.0%, which was significantly lower than 82.4% in the control group, and there were differences between two groups (P<0.05). After treatment, the BMI, ALT, AST, TG, and TC levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, BMI, ALT, AST, TG, and TC levels in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the distribution of the severity of fatty liver and the CT value of liver/spleen in the two groups were significantly improved, and the difference was statistically significant in the same group (P<0.05). After treatment, the distribution of the severity of fatty liver and the CT value of liver/spleen in the treatment group were significantly better than those in the control group, and there were differences between two groups (P<0.05). After treatment, SOD levels was significantly increased in two groups, but MDA and TNF-α levels were significantly decreased, and there were differences in the same group (P<0.05). After treatment, SOD levels in the treatment group were higher than those in the control group, but MDA and TNF-αlevels were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Danning Tablets combined with Tolynicate and Naphthylacetic Acid Tablets has clinical curative effect in treatment of non-alcoholic fatty liver, can effectively reduce the degree of fatty liver, and improve liver function, which has a certain clinical application value.